Science 37 (SNCE)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	56.41 mm	56.41 mm	56.41 mm	56.41 mm	56.41 mm	56.41 mm
Cash burn (monthly)	2.87 mm	6.15 mm	4.85 mm	10.80 mm	133.33 k	4.02 mm
Cash used (since last report)	42.45 mm	91.16 mm	71.83 mm	159.97 mm	1.98 mm	59.50 mm
Cash remaining	13.95 mm	-34.75 mm	-15.42 mm	-103.56 mm	54.43 mm	-3.09 mm
Runway (months of cash)	4.9	-5.6	-3.2	-9.6	408.2	-0.8

Beta Read what these cash burn values mean

Financial data from Science 37 earnings reports.

Institutional ownership, Q2 2023

SNCE institutional ownership history Ownership history

83.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	53	61	-13.1%
Opened positions	12	3	+300.0%
Closed positions	20	8	+150.0%
Increased positions	3	24	-87.5%
Reduced positions	21	11	+90.9%

13F shares	Current	Prev Q	Change
Total value	10.13 bn	14.51 bn	-30.2%
Total shares	99.22 mm	104.01 mm	-4.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Redmile	19.81 mm	$4.21 bn	0.0%
TMO Thermo Fisher Scientific	17.38 mm	$191.70 mm	0.0%
PPD PPD	17.38 mm	$0.00	0.0%
Lux Capital Management	12.25 mm	$69.33 mm	0.0%
LifeSci	4.92 mm	$0.00	0.0%
Russell Investments	3.66 mm	$777.49 mm	0.0%
GLYNN Capital Management	3.54 mm	$752.21 mm	0.0%
Vanguard	3.23 mm	$685.89 mm	-8.8%
GOOG Alphabet	3.21 mm	$673.52 mm	0.0%
MIC Capital Management UK	2.35 mm	$499.68 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	677.90 k	-3.96 mm	-85.4%
STT State Street	197.28 k	-804.74 k	-80.3%
Verition Fund Management	793.28 k	+793.28 k	NEW
Kingswood Wealth Advisors	643.50 k	+643.50 k	NEW
Millennium Management	620.62 k	+620.62 k	NEW
Geode Capital Management	604.60 k	-530.76 k	-46.7%
NTRS Northern Trust	102.84 k	-385.89 k	-79.0%
Y-Intercept	343.35 k	+343.35 k	NEW
Vanguard	3.23 mm	-311.36 k	-8.8%
Rhumbline Advisers	9.11 k	-303.81 k	-97.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SNCE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value
12 Mar 24	David Coman	Common Stock	Sale back to company	Dispose D	No	No	5.75	30,781	176.99 k
12 Mar 24	David Coman	Common Stock		Dispose U	No	No	5.75	53,834	309.55 k
12 Mar 24	David Coman	Stock Option Common Stock	Sale back to company	Dispose D	No	No	5.6	192,427	1.08 mm
12 Mar 24	David Coman	Earn-Out Right Common Stock	Sale back to company	Dispose D	No	No	0	28,899	0.00
12 Mar 24	David Coman	RSU Common Stock	Sale back to company	Dispose D	No	No	0	49,512	0.00
12 Mar 24	Emily Rollins	Common Stock		Dispose U	No	No	5.75	2,050	11.79 k
12 Mar 24	Emily Rollins	Stock Option Common Stock	Sale back to company	Dispose D	No	No	201	1,378	276.98 k
12 Mar 24	Emily Rollins	RSU Common Stock	Sale back to company	Dispose D	No	No	0	24,742	0.00
12 Mar 24	Mike Zaranek	Common Stock	Sale back to company	Dispose D	No	No	5.75	22,212	127.72 k
12 Mar 24	Mike Zaranek	Common Stock		Dispose U	No	No	5.75	9,070	52.15 k

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

21 Nov 24

MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by